重组人血管内皮抑素联合紫杉醇化疗对人乳腺癌MDA-MB-435细胞抗凋亡基因Bcl-2的影响  

Influence mechanism of Endostar combined with Paclitaxel on human breast cancer MDA-MB-435 cell apoptosis gene Bcl-2

作　　者：姜秋颖[1] 金英华[1] 张冉冉[1] 陈春红[1] 黄大勇[1] 吕艳菊[1] 信涛[1] 申维喜[1] 

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤内科,黑龙江哈尔滨150086

出　　处：《中国医药导报》2016年第35期92-95,共4页China Medical Herald

基　　金：黑龙江省卫生厅科研课题(2012-641)

摘　　要：目的探讨重组人血管内皮抑素(恩度)联合紫杉醇对人乳腺癌MDA-MB-435细胞抗凋亡基因Bcl-2的影响。方法将BALB/c裸鼠32只进行细胞培养,随机分为4组,其中3个化疗组(恩度组、紫杉醇组及恩度联合紫杉醇组)和1个对照组,每组8只。化疗组为腹腔注射给药,第1、8天各给药1次,给药剂量:恩度10 mg/kg、紫杉醇注射液10 mg/kg。对照组腹腔注射生理盐水,第1、8天各注射1次。给药15 d后处死小鼠并取出瘤体,将瘤体组织行HE染色和免疫组化SP法染色。原位末端标记法检测细胞凋亡,并计算癌细胞凋亡指数(AI)。结果恩度组、紫杉醇组及恩度联合紫杉醇组Bcl-2表达均显著低于对照组,差异有统计学意义(P<0.05)。恩度联合紫杉醇组Bcl-2表达分别显著低于恩度组、紫杉醇组,差异有统计学意义(P<0.05)。恩度组、紫杉醇组及恩度联合紫杉醇组AI均显著高于对照组,差异有统计学意义(P<0.05)。恩度联合紫杉醇组AI分别显著高于恩度组、紫杉醇组,差异有统计学意义(P<0.05)。结论抗凋亡基因Bcl-2可能参与了乳腺癌的发生、发展过程,恩度联合紫杉醇化疗可降低Bcl-2表达,促进乳腺癌细胞凋亡,因此,Bcl-2水平检测在恩度联合紫杉醇治疗乳腺癌效果及预后评估中有重要的参考价值。Objective To investigate the effects of Endostar combined with Paclitaxel anti apoptosis gene Bcl-2 on hu- man breast cancer cell line MDA-MB-435. Methods 32 BALB/c mice were cultured and randomly divided into four groups, 3 chemotherapy groups （Endostar group, Paclitaxel group and Endostar combined with Paclitaxel group） and 1 control group, 8 rats in each group. Chemotherapy groups were given intraperitoneal injection,at the first and eighth days respectively administered 1 times. Dosage： Endostar 10 mg/kg, Paclitarel injection 10 mg/kg. Control group re- ceived intraperitoneal injection of normal saline, at the first and eighth days respectively administered 1 times. After treatment for 15 d, mice were killed and the tumors were removed, HE staining and immunohistoehemical SP staining were performed in the tumor tissues. Apoptosis was detected by TUNEL method, and the apoptosis index （AI） of the cancer cells was calculated. Results The expression of Bcl-2 in Endostar group, Paclitaxel group and Endostar com- bined with Paclitaxel group was respectively significantly higher than that of the control group, the difference was sig- nificant （P 〈 0.05）. And the expression of Bcl-2 in Endostar combined with Paclitaxel group was significantly higher than that of Endostar group, Paclitaxel group respectively, the difference was significant （P 〈 0.05）. The AI of Endostar group, Paclitaxel group and Endostar combined with Paclitaxel group was respectively significantly higher than that of the control group, the difference was significant （P 〈 0.05）. And AI of Endostar combined with Paclitaxel group was significantly higher than that of Endostar group, Paclitaxel group respectively, the difference was significant （P 〈 0.05）. Conclusion The anti apoptotic gene Bcl-2 is involved in the development and progression of breast cancer, combined with Paclitaxel chemotherapy for apoptosis of breast cancer patients by monitoring the expression of anti apoptosis gene Bcl-2 in breast cancer combined

关 键 词：乳腺癌 抗凋亡基因BCL-2 恩度联合紫杉醇 化疗 

分 类 号：R655.7[医药卫生—外科学]